Leap Therapeutics Inc. (LPTX) has several pivotal clinical trial milestones to watch for in the coming months, particularly regarding its lead drug candidate, DKN-01, an anti-DKK1 monoclonal antibody.
DKN-01 is being tested in combination with standard therapies for advanced colorectal and gastric cancers. A phase II trial evaluating DKN-01 in combination with bevacizumab and chemotherapy for second-line treatment of advanced colorectal cancer, dubbed DeFianCe, is underway. Enrollment in the expanded randomized controlled Part B of the DeFianCe study has been completed, with initial results expected in mid-2025.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.